Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shenlingbaizhu granules and/or pidotimod for children with recurrent respiratory tract infections in remission
ChiCTR-TRC-11001511Phase 4Completed
- Sponsor
- Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine
- Start
- Oct 2011
- Modality
- Small Molecules, Peptides, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of shenlingbaizhu granules and pidotimod in recurrent respiratory tract infection (RRTI) (4 arms), sponsored by Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine. Primary endpoints: Number of acute respiratory tract infection attacks within 1 year, Serum immunoglobulins and 2 more. Started Oct 2011; status: completed.
02
Drugs
shenlingbaizhu granulespidotimod
03
Conditions
recurrent respiratory tract infection (RRTI)
Beyond the preview
Go deeper on ChiCTR-TRC-11001511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-11001511.